Bezafibrate improves postprandial hypertriglyceridemia and associated endothelial dysfunction in patients with metabolic syndrome: A randomized crossover study

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Ohno, Yuko ^a   Miyoshi, Toru ^a   Noda, Yoko ^a   Oe, Hiroki ^b   Toh, Norihisa ^a   Nakamura, Kazufumi ^a   Kohno, Kunihisa ^a   Morita, Hiroshi ^a   Ito, Hiroshi ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Atherosclerosis; Bezafibrate; Endothelium; Triglyceride; Vasodilation

Indexed keywords

APOLIPOPROTEIN B; BEZAFIBRATE; CHOLESTEROL; CHYLOMICRON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PENTRAXIN 3; REMNANT LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VERY LOW DENSITY LIPOPROTEIN;

ADULT; AGED; ARTERY DILATATION; ARTICLE; BRACHIAL ARTERY FLOW MEDIATED DILATION; CHOLESTEROL BLOOD LEVEL; CHROMATOGRAPH; CLINICAL ARTICLE; CONTROLLED STUDY; COOKIE TEST; CROSSOVER PROCEDURE; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTRIGLYCERIDEMIA; INSULIN BLOOD LEVEL; LIPID ANALYSIS; MALE; METABOLIC SYNDROME X; OUTCOME ASSESSMENT; POSTPRANDIAL HYPERTRIGLYCERIDEMIA; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; TEST MEAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; VERY ELDERLY;

ADULT; BEZAFIBRATE; CROSS-OVER STUDIES; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYPERTRIGLYCERIDEMIA; HYPOLIPIDEMIC AGENTS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; POSTPRANDIAL PERIOD; SINGLE-BLIND METHOD;

EID: 84898034958     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-71     Document Type: Article

References (41)

1. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298(3):309-316. 10.1001/jama.298.3.309, 17635891.
2. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298(3):299-308. 10.1001/jama.298.3.299, 17635890.
3. Botham KM, Wheeler-Jones CP. Postprandial lipoproteins and the molecular regulation of vascular homeostasis. Prog Lipid Res 2013, 52(4):446-464. 10.1016/j.plipres.2013.06.001, 23774609.
4. Nakano T, Nakajima K, Niimi M, Fujita MQ, Nakajima Y, Takeichi S, Kinoshita M, Matsushima T, Teramoto T, Tanaka A. Detection of apolipoproteins B-48 and B-100 carrying particles in lipoprotein fractions extracted from human aortic atherosclerotic plaques in sudden cardiac death cases. Clin Chim Acta 2008, 390(1-2):38-43.
5. Bae JH, Bassenge E, Kim KB, Kim YN, Kim KS, Lee HJ, Moon KC, Lee MS, Park KY, Schwemmer M. Postprandial hypertriglyceridemia impairs endothelial function by enhanced oxidant stress. Atherosclerosis 2001, 155(2):517-523. 10.1016/S0021-9150(00)00601-8, 11254924.
6. van Oostrom AJ, Sijmonsma TP, Verseyden C, Jansen EH, de Koning EJ, Rabelink TJ, Castro Cabezas M. Postprandial recruitment of neutrophils may contribute to endothelial dysfunction. Journal of lipid research 2003, 44(3):576-583. 10.1194/jlr.M200419-JLR200, 12562833.
7. Tenenbaum A, Fisman EZ. Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction. Cardiovasc Diabetol 2012, 11:125. 10.1186/1475-2840-11-125, 3489608, 23057687.
8. Tenenbaum A, Fisman EZ. Balanced pan-PPAR activator bezafibrate in combination with statin: comprehensive lipids control and diabetes prevention?. Cardiovasc Diabetol 2012, 11:140. 10.1186/1475-2840-11-140, 3502168, 23150952.
9. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S. Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004, 109(18):2197-2202. 10.1161/01.CIR.0000126824.12785.B6, 15123532.
10. Meco JF, Vila R, Pujol R, Bros R, Domenech P, Fiol C, Pinto X. Improvement in endothelial dysfunction in patients with hypoalphalipoproteinemia and coronary artery disease treated with bezafibrate. J Cardiovasc Pharmacol 2001, 38(2):250-258. 10.1097/00005344-200108000-00011, 11483875.
11. Nakamura T, Takano H, Umetani K, Kawabata K, Obata JE, Kitta Y, Kodama Y, Mende A, Ichigi Y, Fujioka D, Saito Y, Kugiyama K. Remnant lipoproteinemia is a risk factor for endothelial vasomotor dysfunction and coronary artery disease in metabolic syndrome. Atherosclerosis 2005, 181(2):321-327. 10.1016/j.atherosclerosis.2005.01.012, 16039286.
12. Evans M, Anderson RA, Graham J, Ellis GR, Morris K, Davies S, Jackson SK, Lewis MJ, Frenneaux MP, Rees A. Ciprofibrate therapy improves endothelial function and reduces postprandial lipemia and oxidative stress in type 2 diabetes mellitus. Circulation 2000, 101(15):1773-1779. 10.1161/01.CIR.101.15.1773, 10769276.
13. Wilmink HW, Twickler MB, Banga JD, Dallinga-Thie GM, Eeltink H, Erkelens DW, Rabelink TJ, Stroes ES. Effect of statin versus fibrate on postprandial endothelial dysfunction: role of remnant-like particles. Cardiovasc Res 2001, 50(3):577-582. 10.1016/S0008-6363(01)00227-9, 11376633.
14. Attia N, Durlach V, Cambilleau M, Roche D, Girard-Globa A. Postprandial concentrations and distribution of apo C-III in type 2 diabetic patients. Effect Of bezafibrate treatment. Atherosclerosis 2000, 149(2):427-433. 10.1016/S0021-9150(99)00337-8, 10729394.
15. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006, 23(5):469-480. 10.1111/j.1464-5491.2006.01858.x, 16681555.
16. Yunoki K, Nakamura K, Miyoshi T, Enko K, Kohno K, Morita H, Kusano KF, Ito H. Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Atherosclerosis 2011, 217(2):486-491. 10.1016/j.atherosclerosis.2011.04.019, 21592480.
17. Harano Y, Miyawaki T, Nabiki J, Shibachi M, Adachi T, Ikeda M, Ueda F, Nakano T. Development of cookie test for the simultaneous determination of glucose intolerance, hyperinsulinemia, insulin resistance and postprandial dyslipidemia. Endocrine journal 2006, 53(2):173-180. 10.1507/endocrj.53.173, 16618974.
18. Usui S, Hara Y, Hosaki S, Okazaki M. A new on-line dual enzymatic method for simultaneous quantification of cholesterol and triglycerides in lipoproteins by HPLC. J Lipid Res 2002, 43(5):805-814.
19. Corretti MC, Anderson TJ, Benjamin EJ, Celermajer D, Charbonneau F, Creager MA, Deanfield J, Drexler H, Gerhard-Herman M, Herrington D, Vallance P, Vita J, Vogel R. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39(2):257-265. 10.1016/S0735-1097(01)01746-6, 11788217.
20. Olijhoek JK, Hajer GR, van der Graaf Y, Dallinga-Thie GM, Visseren FL. The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial. J Cardiovasc Pharmacol 2008, 52(2):145-150. 10.1097/FJC.0b013e31817ffe76, 18670365.
21. Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 2007, 30(8):1945-1951. 10.2337/dc07-0015, 17483155.
22. Wang TY, Liu M, Portincasa P, Wang DQ. New insights into the molecular mechanism of intestinal fatty acid absorption. Eur J Clin Invest 2013, 43(11):1203-1223.
23. Sandoval JC, Nakagawa-Toyama Y, Masuda D, Tochino Y, Nakaoka H, Kawase R, Yuasa-Kawase M, Nakatani K, Inagaki M, Tsubakio-Yamamoto K, Ohama T, Nishida M, Ishigami M, Komuro I, Yamashita S. Fenofibrate reduces postprandial hypertriglyceridemia in CD36 knockout mice. J Atheroscler Thromb 2010, 17(6):610-618. 10.5551/jat.3988, 20351468.
24. Heller F, Harvengt C. Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects. Eur J Clin Pharmacol 1983, 25(1):57-63. 10.1007/BF00544015, 6617725.
25. Murakami H, Murakami R, Kambe F, Cao X, Takahashi R, Asai T, Hirai T, Numaguchi Y, Okumura K, Seo H, Murohara T. Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC. Biochem Biophys Res Commun 2006, 341(4):973-978. 10.1016/j.bbrc.2006.01.052, 16442496.
26. Wang Y, Yang Q, Yan JT, Zhao C, Cianflone K, Wang DW. Effects of bezafibrate on the expression of endothelial nitric oxide synthase gene and its mechanisms in cultured bovine endothelial cells. Atherosclerosis 2006, 187(2):265-273. 10.1016/j.atherosclerosis.2005.09.008, 16256120.
27. Krysiak R, Okopien B. Effect of bezafibrate on monocyte cytokine release and systemic inflammation in patients with impaired fasting glucose. J Clin Pharmacol 2011, 51(10):1459-1467. 10.1177/0091270010382914, 21119093.
28. Norata GD, Grigore L, Raselli S, Redaelli L, Hamsten A, Maggi F, Eriksson P, Catapano AL. Post-prandial endothelial dysfunction in hypertriglyceridemic subjects: molecular mechanisms and gene expression studies. Atherosclerosis 2007, 193(2):321-327. 10.1016/j.atherosclerosis.2006.09.015, 17055512.
29. Garlanda C, Bottazzi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2005, 23:337-366. 10.1146/annurev.immunol.23.021704.115756, 15771574.
30. Rolph MS, Zimmer S, Bottazzi B, Garlanda C, Mantovani A, Hansson GK. Production of the long pentraxin PTX3 in advanced atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2002, 22(5):e10-e14. 10.1161/01.ATV.0000015595.95497.2F, 12006411.
31. Suzuki S, Takeishi Y, Niizeki T, Koyama Y, Kitahara T, Sasaki T, Sagara M, Kubota I. Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. Am Heart J 2008, 155(1):75-81. 10.1016/j.ahj.2007.08.013, 18082493.
32. The BIP Study Group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease. Circulation 2000, 102(1):21-27. The BIP Study Group.
33. Goldenberg I, Benderly M, Sidi R, Boyko V, Tenenbaum A, Tanne D, Behar S. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). Am J Cardiol 2009, 103(1):41-45. 10.1016/j.amjcard.2008.08.033, 19101227.
34. Tenenbaum A, Motro M, Fisman EZ, Adler Y, Shemesh J, Tanne D, Leor J, Boyko V, Schwammenthal E, Behar S. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 2005, 26(19):2032-2038. 10.1093/eurheartj/ehi310, 15872029.
35. Teramoto T, Shirai K, Daida H, Yamada N. Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study. Cardiovasc Diabetol 2012, 11:29. 10.1186/1475-2840-11-29, 3342914, 22439599.
36. Triolo M, Annema W, de Boer JF, Tietge UJ, Dullaart RP. Simvastatin and bezafibrate increase cholesterol efflux in men with type 2 diabetes. Eur J Clin Invest 2014, 44(3):240-248. 10.1111/eci.12226, 24325778.
37. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005, 165(10):1154-1160. 10.1001/archinte.165.10.1154, 15911729.
38. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006, 48(3):438-445. 10.1016/j.jacc.2006.04.070, 16875966.
39. Jukema JW, Cannon CP, de Craen AJ, Westendorp RG, Trompet S. The controversies of statin therapy: weighing the evidence. J Am Coll Cardiol 2012, 60(10):875-881. 10.1016/j.jacc.2012.07.007, 22902202.
40. Pauciullo P, Borgnino C, Paoletti R, Mariani M, Mancini M. Efficacy and safety of a combination of fluvastatin and bezafibrate in patients with mixed hyperlipidaemia (FACT study). Atherosclerosis 2000, 150(2):429-436. 10.1016/S0021-9150(00)00379-8, 10856536.
41. Tenenbaum A, Medvedofsky D, Fisman EZ, Bubyr L, Matetzky S, Tanne D, Klempfner R, Shemesh J, Goldenberg I. Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: acute Coronary Syndrome Israeli Surveys data. PLoS One 2012, 7(4):e35298. 10.1371/journal.pone.0035298, 3327654, 22523582.